Keros Therapeutics, Inc. (KROS)
11.67
-0.05
(-0.43%)
USD |
NASDAQ |
Apr 17, 16:00
11.90
+0.23
(+1.97%)
After-Hours: 20:00
Keros Therapeutics SG&A Expense (Quarterly) : 11.74M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 128.30M |
| PTC Therapeutics, Inc. | 96.87M |
| Amicus Therapeutics, Inc. | 117.08M |
| MannKind Corp. | 58.41M |
| Insmed, Inc. | 212.48M |